top of page
< Back

Denosumab


Mechanism of action:

Denosumab is a monoclonal antibody that specifically binds to RANKL (receptor activator of nuclear factor kappa-B ligand). Under normal physiology, osteoblasts secrete RANKL, which then binds to RANK on osteoclast precursor cells and promotes osteoclast maturation and activation. Osteoclasts are responsible for bone resorption. When denosumab binds to RANKL, RANK can no longer be activated, thereby inhibiting osteoclast formation, differentiation, and survival. By reducing bone resorption, denosumab increases bone density and bone strength.

Reference(s):

1. Malan J et al. (2012). The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 


2. Stefania S et al. (2023). Role of denosumab in bone erosions in rheumatoid arthritis. Postgrad Med J.

bottom of page